Current status of gynecologic cancer in Japan

Journal of Gynecologic Oncology

Volumn 20, Issue 2, 2009, Pages 67-71

  Ushijima, Kimio ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adjuvant chemotherapy; Cervical cancer; Endometrial cancer; Epidemiology; Fertility preservation; Ovarian cancer

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC METAL COMPLEX; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; IRINOTECAN; MEDROXYPROGESTERONE; PACLITAXEL;

ANEMIA; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER THERAPY; CLINICAL TRIAL; ENDOMETRIUM CARCINOMA; FERTILITY; GYNECOLOGIC CANCER; HUMAN; JAPAN; JAPANESE; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; OVARY; OVARY CANCER; REVIEW; UTERINE CERVIX CANCER; UTERUS;

EID: 77950960064     PISSN: 20050380     EISSN: 20050399     Source Type: Journal    
DOI: 10.3802/jgo.2009.20.2.67     Document Type: Review

References (14)

1. Oshima A, Kuroisi T, Tajima K. Cancer statistic statement. Tokyo: Shinohara Publishing; 2004.
2. Report from gynecologic tumor committee of JSOG. Acta Obstet Gynaecol Jpn 2007; 59: 952.
3. Report from gynecologic tumor committee of JSOG. Acta Obstet Gynaecol Jpn 2009; 61: 936.
4. Report from gynecologic tumor committee of JSOG. Acta Obstet Gynaecol Jpn 2000; 52: 855.
5. Kaku T, Yoshikawa H, Tsuda H, Sakamoto A, Fukunaga M, Kamura T, et al. Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women: central pathologic review and treatment outcome. Cancer Lett 2001; 167: 39-48. (Pubitemid 32373267)
6. Ushijima K, Yahata H, Yoshikawa H, Konishi I, Yasugi T, Saito T, et al. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol 2007; 25: 2798-2803 (Pubitemid 47123189)
7. Japan Society of Gynecologic Oncology. Ovarian cancer treatment guidelines 2007. Tokyo: Kanehara & Co. Ltd; 2007.
8. Susumu N, Sagae S, Udagawa Y, Niwa K, Kuramoto H, Satoh S, et al. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecol Oncol 2008; 108: 226-233 (Pubitemid 350299451)
9. Rose PG, Smrekar M, Fusco N. A phase II trial of weekly paclitaxel and every 3 weeks of carboplatin in potentially platinum-sensitive ovarian and peritoneal carcinoma. Gynecol Oncol 2005; 96: 296-300. (Pubitemid 40127124)
10. Isonishi S, Yasuda M, Takahashi F, Katsumata N, Kimura E, Aoki D, et al. Randomized phase III trial of conventional paclitaxel and carboplatin (c-TC) versus dose dense weekly paclitaxel and carboplatin (dd-TC) in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: Japanese Gynecologic Oncology [abstract]. J Clin Oncol 2008: 26(15S); abstr 5506.
11. Taguchi K. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 2000; 88: 2584-2589 (Pubitemid 30331967)
12. Enomoto T, Kuragaki C, Yamasaki M, Sugita N, Otsuki Y, Ikegami H, et al. Is clear cell carcinoma and mucinous carcinoma of the ovary sensitive to combination chemotherapy with paclitaxel and carboplatin? [abstract]. Proc Am Soc Clin Oncol 2003: 22; abstr 1797.
13. Sugiyama T, Yakushiji M, Nishida T, Ushijima K, Okura N, Kigawa J, et al. Irinotecan (CPT-11) combined with cisplatin in patients with refractory or recurrent ovarian cancer. Cancer Lett 1998; 128: 211-218 (Pubitemid 28318738)
14. Takano M, Kikuchi Y, Yaegashi N, Suzuki M, Tsuda H, Sagae S, et al. Adjuvant chemotherapy with irinotecan hydrochloride and cisplatin for clear cell carcinoma of the ovary. Oncol Rep 2006; 16: 1301-1306 (Pubitemid 43772268)